

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter J. Houzego, Peter N. Morgan, Peter H. Hirst, Duncan J. Westland and
Ian R. Wilding

Serial No.: 10/607,721

Art Unit: Not Yet Assigned

Filed: June 27, 2003

Examiner: Not Yet Assigned

For: *AN INGESTIBLE DEVICE*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the eleven (11) documents cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

Publications

CENTURY SPRING CORP., *Spec Sheet for Compression Spring Part No. 70545* (2003).

COOK, et al., "Non-invasive site absorption studies of an aldosterone antagonist (SC-66110) in beagles using a remote control capsule (InteliSite®) and gamma scintigraphy," *Pharm. Sci. Suppl.* 1(1): S-139 (1998).

DIGENIS, et al., "Acceleration of pharmaceutical research and development with application of gamma scintigraphy," *Eur. Pharm. Contractor*, pp. 22-32 (1999).

DIGENIS, et al., "Gamma scintigraphy: an evolving technology in pharmaceutical formulation development – Part 1," *Pharm. Sci. & Tech. Today* 1(3): 100-107 (1998).

DIGENIS, et al., "Gamma scintigraphy: an evolving technology in pharmaceutical formulation development – Part 2," *Pharm. Sci. & Tech. Today* 1(4): 160-165 (1998).

DOLL, et al., "A bioavailability study of leuprolide acetate directly released in the ileum and colon of healthy human subjects using gamma scintigraphy and the InteliSite® capsule," *Pharm. Res.* 14(9): S-654 (1997).

GARDNER, et al., "Noninvasive methodology for assessing regional drug absorption from the gastrointestinal tract," *Pharm. Tech.*, pp. 82-89 (1997).

PARR, et al., "Evaluation of a prototype remote drug delivery capsule (RDDC) in healthy adult volunteers for non-invasive regional drug absorption studies in the GI tract of man," *Pharm. Res.* 14(9): S-654 (1997).

PARR, et al., "Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and beagle dog," *Pharm. Res.* 16(2): 266-271 (1999).

PITHAVALA, et al., "Use of the InteliSite® capsule to study ranitidine absorption from various sites within the human intestinal tract," *Pharm. Res.* 15(12): 1869-1875 (1998).


SANDEFER, "Contributions of gamma scintigraphy to the in vivo evaluation of oral dosage forms: implications of gastrointestinal transit times and the effect on drug absorption," *Doctoral Dissertation, University of Kentucky College of Pharmacy* (1996).

U.S.S.N.: 10/607,721
Filed: June 27, 2003
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: February 2, 2004

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 10/607,721
Filed: June 27, 2003
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT


Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: February 2, 2004


Peggy Bailey

1575013_v1



Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/607,721
Filing Date	June 27, 2003
First Named Inventor	Peter J. Houzago
Group Art Unit	
Examiner Name	
Attorney Docket Number	PHAG 100 DIV

Sheet	1	of	2
-------	---	----	---

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CENTURY SPRING CORP., <i>Spec Sheet for Compression Spring Part No. 70545</i> (2003).	
		COOK, et al., "Non-invasive site absorption studies of an aldosterone antagonist (SC-66110) in beagles using a remote control capsule (InteliSite®) and gamma scintigraphy," <i>Pharm. Sci. Suppl.</i> 1(1): S-139 (1998).	
		DIGENIS, et al., "Acceleration of pharmaceutical research and development with application of gamma scintigraphy," <i>Eur. Pharm. Contractor</i> , pp. 22-32 (1999).	
		DIGENIS, et al., "Gamma scintigraphy: an evolving technology in pharmaceutical formulation development - Part 1," <i>Pharm. Sci. & Tech. Today</i> 1(3): 100-107 (1998).	
		DIGENIS, et al., "Gamma scintigraphy: an evolving technology in pharmaceutical formulation development - Part 2," <i>Pharm. Sci. & Tech. Today</i> , 1(4): 160-165 (1998).	
		DOLL, et al., "A bioavailability study of leuprolide acetate directly released in the ileum and colon of healthy human subjects using gamma scintigraphy and the InteliSite® capsule," <i>Pharm. Res.</i> 14(9): S-654 (1997).	
		GARDNER, et al., "Noninvasive methodology for assessing regional drug absorption from the gastrointestinal tract," <i>Pharm. Tech.</i> , pp. 82-89 (1997).	
		PARR, et al., "Evaluation of a prototype remote drug delivery capsule (RDDC) in healthy adult volunteers for non-invasive regional drug absorption studies in the GI tract of man," <i>Pharm. Res.</i> 14(9): S-654 (1997).	
		PARR, et al., "Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and beagle dog," <i>Pharm. Res.</i> 16(2): 266-271 (1999).	
		PITHAVALA, et al., "Use of the InteliSite® capsule to study ranitidine absorption from various sites within the human intestinal tract," <i>Pharm. Res.</i> 15(12): 1869-1875 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

PTO/SB/DRA (10-98)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

10/607,721

Filing Date

June 27, 2003

First Named Inventor

Peter J. Houzego

Group Art Unit

Examiner Name

Attorney Docket Number

PHAG 100 DIV

Sheet

2

of

2

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.